INZOLI, ELENA
INZOLI, ELENA
DIPARTIMENTO DI MEDICINA E CHIRURGIA (SCHOOL OF MEDICINE AND SURGERY)
First-hit SETBP1 mutations cause a myeloproliferative disorder with bone marrow fibrosis
2024 Crespiatico, I; Zaghi, M; Mastini, C; D'Aliberti, D; Mauri, M; Mercado, C; Fontana, D; Spinelli, S; Crippa, V; Inzoli, E; Manghisi, B; Civettini, I; Ramazzotti, D; Sangiorgio, V; Gengotti, M; Brambilla, V; Aroldi, A; Banfi, F; Barone, C; Orsenigo, R; Riera, L; Riminucci, M; Corsi, A; Breccia, M; Morotti, A; Cilloni, D; Roccaro, A; Sacco, A; Stagno, F; Serafini, M; Mottadelli, F; Cazzaniga, G; Pagni, F; Chiarle, R; Azzoni, E; Sessa, A; Gambacorti Passerini, C; Elli, E; Mologni, L; Piazza, R
Biosimilar erythropoiesis-stimulating agents are an effective and safe option for the management of myelofibrosis-related anemia
2023 Inzoli, E; Crisa, E; Pugliese, N; Civettini, I; Lanzarone, G; Castelli, A; Martinelli, V; Montelisciani, L; Antolini, L; Gambacorti-Passerini, C; Elli, E
DNA Damage Response (DDR) Is Associated With Treatment-free Remission in Chronic Myeloid Leukemia Patients
2023 Malighetti, F; Arosio, G; Manfroni, C; Mauri, M; Villa, M; Manghisi, B; Inzoli, E; Rindone, G; Zambrotta, G; Civettini, I; Guglielmana, V; Ramazzotti, D; Giudici, G; Bombelli, S; Perego, R; Piazza, R; Mologni, L; Gambacorti-Passerini, C
Tyrosine Kinase Inhibitor discontinuation in Chronic Myeloid Leukemia: eligibility criteria and predictors of success
2022 Inzoli, E; Aroldi, A; Piazza, R; Gambacorti Passerini, C